Company News »

Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Ambit Biosciences Corporation Stockholders

Business Wire
Share on StockTwits
Published on

Kirby McInerney LLP is investigating potential claims against Ambit Biosciences Corporation (“Ambit Biosciences” or the “Company”) (NASDAQ:AMBI) concerning the proposed acquisition of the Company by Daiichi Sankyo Company, Ltd. (“Daiichi Sankyo”) (TYO: 4568). Under the terms of the definitive merger agreement, Ambit Biosciences stockholders will receive $15.00 in cash for each share of Ambit Biosciences common stock they own and one Contingent Value Right (“CVR”) entitling the holder to receive an additional cash payment of up to $4.50 for each share of Ambit Biosciences common stock they own if certain commercialization related milestones are achieved. The total transaction is valued at up to $410 million.

The investigation concerns whether the Ambit Biosciences Board of Directors violated its fiduciary duties by agreeing to the proposed transaction and whether the proposed consideration adequately values the Company’s common stock.

If you are an Ambit Biosciences stockholder and wish to obtain additional information, please contact J. Brandon Walker, Esq. by email at bwalker@kmllp.com, or telephone at (212) 699-1145, Melissa Fortunato, Esq. by email at mfortunato@kmllp.com, or telephone at (212) 699-1141, or toll free at (888) 529-4787, or by filling out this contact form. There is no cost or obligation to you.

Kirby McInerney LLP is a New York-based law firm concentrating in securities, whistleblower, antitrust and consumer litigation. For additional information, please go to www.kmllp.com.

Share on StockTwits